title: [Effect of DL-carnitine and gamma-butyrobetaine hydroxylase inhibitor 3-(2,2,2-trimethylhydrazinium) propionate on isoproterenol-induced changes in the metabolism of the rat myocardium].
abstract: 3-(2,2,2-trimethyl hydrazinium) propionate (THP) is known as an inhibitor of gamma-butyrobetaine hydroxylase in rat liver tissue. At the same time, THP, administered per os at a dose of 100 mg/kg within 10 days, prevented the isoproterenol-induced (subcutaneously, 50 mg/kg) acylcarnitine accumulation. This effect of THP, accompanied by a distinct decrease of free carnitine in rat myocardium, occurred due to inhibition of carnitine biosynthesis from gamma-butyrobetaine. THP protected the myocardium energetics against isoproterenol action as the drug prevented the acylcarnitine accumulation. Although D,L-carnitine (200 mg/kg, per os, 10 days) inhibited also the isoproterenol-stimulated acylcarnitine accumulation in rat myocardium and fatty acids of blood serum, in did not exhibit any favourable effect on myocardium bioenergetics. Inefficiency of D,L-carnitine as cardioprotective drug may be a result of intensification of fatty acids metabolism occurring simultaneously with isoproterenol-mediated myocardium ischemia. Use of inhibitors of carnitine-dependent oxidation of fatty acids oxidation (as exemplified by THP) in order to correct myocardium metabolism is of importance especially in relation to impairing effects caused by catecholamines.
authors.forename: B Z
authors.initials: BZ
authors.lastname: Simkhovich
authors.forename: D V
authors.initials: DV
authors.lastname: Meĭrena
authors.forename: Zh V
authors.initials: ZhV
authors.lastname: Shutenko
authors.forename: Kh B
authors.initials: KhB
authors.lastname: Khagi
authors.forename: Ia L
authors.initials: IaL
authors.lastname: Briede
mesh_terms: D000108:Acetylcarnitine / Q000378:metabolism; D000244:Adenosine Diphosphate / Q000378:metabolism; D000249:Adenosine Monophosphate / Q000378:metabolism; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D002331:Carnitine / Q000494:pharmacology*; D003327:Coronary Disease / Q000139:chemically induced / Q000378:metabolism* / Q000517:prevention & control; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D007545:Isoproterenol / Q000633:toxicity; D008297:Male; D008763:Methylhydrazines / Q000494:pharmacology*; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors*; D009206:Myocardium / Q000378:metabolism*; D051381:Rats; D050563:gamma-Butyrobetaine Dioxygenase
chemical_list: D005230:Fatty Acids, Nonesterified; D008763:Methylhydrazines; D000249:Adenosine Monophosphate; D000244:Adenosine Diphosphate; D000108:Acetylcarnitine; C050147:3-(2,2,2-trimethylhydrazine)propionate; D000255:Adenosine Triphosphate; D006899:Mixed Function Oxygenases; D050563:gamma-Butyrobetaine Dioxygenase; D007545:Isoproterenol; D002331:Carnitine
vernacular_title: Vliianie DL-karnitina i ingibitora gamma-butirobetaingidroksilazy 3-(2,2,2-trimetilgidraziniĭ) propionata (TGP) na vyzyvaemye isoproterenolom izmeneniia v metabolizme miokarda krys.